Are we improving the long-term burden of Hodgkin's lymphoma patients with modern treatment?
The cure rate of patients who have Hodgkin's lymphoma (HL) amounts to 80% or more because of risk-adapted treatment using modern chemotherapy and radiotherapy schedules. In this article we describe important late effects after treatment of HL and how we expect the long-term burden of patients who have HL to change applying modern treatments. Because treatment always has side effects to some extent, awareness of possible late effects after treatment remains important for patients and treating physicians.
Aleman
Berthe M P
BM
Department of Radiotherapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. b.aleman@nki.nl
van Leeuwen
Flora E
FE
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000150:complications / Q000628:therapy*; D006801:Humans; D015182:Lymphatic Irradiation / Q000009:adverse effects; D016609:Neoplasms, Second Primary; D011788:Quality of Life; D012307:Risk Factors; D016019:Survival Analysis; D017741:Survivors